Quest PharmaTech Inc. Signs Exclusive License Agreement With University of California, Los Angeles (UCLA) for Anti - PSA IgE Technology; UCLA researchers to Present Anti - PSA IgE Preclinical Data at the 2013 American Association for Cancer Research Conference
4/9/2013 9:43:30 AM
More...
|
Quest PharmaTech Inc. Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.
1/22/2013 10:32:05 AM
More...
|
Quest PharmaTech Inc. Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy
7/10/2012 9:33:21 AM
More...
|
Quest PharmaTech Inc. Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States
6/14/2012 11:15:55 AM
More...
|
Quest PharmaTech Inc. Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs
6/6/2012 10:23:06 AM
More...
|
Quest PharmaTech Inc. Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based on Nanotechnology
11/29/2011 12:42:31 PM
More...
|
Quest PharmaTech Inc. Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)
11/1/2011 11:06:04 AM
More...
|
Quest PharmaTech Inc. Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherapy for the Treatment of Cancer
7/21/2011 10:40:03 AM
More...
|
Quest PharmaTech Inc. Provides Oregovomab Chemo Immunotherapy Clinical Trial and other Corporate Updates
6/7/2011 11:29:50 AM
More...
|
Quest PharmaTech Inc. Announces Clinical Development Agreement with Hemispherx Biopharma (HEB) to Evaluate a Combinatorial Immunotherapy Technology
4/14/2011 10:38:30 AM
More...
|
|